TY - JOUR
T1 - Multipotent and Committed CD34+ Cells in Bone Marrow Transplantation
AU - Ema, Hideo
AU - Suda, Toshio
AU - Nakauchi, Hiromitsu
AU - Nakamura, Yukio
AU - Iwama, Atsushi
AU - Imagawa, Shigehiko
AU - Akutsu, Miyuki
AU - Kano, Yasuhiko
AU - Kato, Shunichi
AU - Yabe, Miharu
AU - Yoshida, Minoru
AU - Sakamoto, Shinobu
AU - Amemiya, Youichi
AU - Miura, Yasusada
PY - 1991/5
Y1 - 1991/5
N2 - In order to study the role of CD34+ cells in hematological recovery following bone marrow transplantation (BMT), bone marrow cells stained with HPCA‐1 (CD34) and MY‐9 (CD33) monoclonal antibodies were analyzed by using a fluorescence‐activated cell sorter on or about days 14 and 28, as well as at later times, following BMT in 6 recipients. Single cell cultures of CD34+ cells were also performed to evaluate their in vitro hematopoietic function. CD34+ cells were detectable in bone marrow cells on day 14. More than 80% of CD34+ cells co‐expressed the CD33 antigen, and macrophage (Mac) colony‐forming cells predominated among total colony‐forming cells of CD34+ cells. In normal bone marrow cells, CD34+, CD33+ cells amounted to about 40% of CD34+ cells, and the incidences of erythroid bursts, granulocyte/macrophage (GM) colonies, and Mac colonies were similar to each other. After more than 10 weeks, CD34+, CD33− cells gradually recovered, as erythroid burst colony‐forming cells increased following GM colony‐forming cells. This phenomenon was well‐correlated with the time course of peripheral blood cell recovery. CD34+, CD33+ cells as committed progenitors and CD34+, CD33− cells as multipotent stem cells have distinctive biological behaviors in BMT.
AB - In order to study the role of CD34+ cells in hematological recovery following bone marrow transplantation (BMT), bone marrow cells stained with HPCA‐1 (CD34) and MY‐9 (CD33) monoclonal antibodies were analyzed by using a fluorescence‐activated cell sorter on or about days 14 and 28, as well as at later times, following BMT in 6 recipients. Single cell cultures of CD34+ cells were also performed to evaluate their in vitro hematopoietic function. CD34+ cells were detectable in bone marrow cells on day 14. More than 80% of CD34+ cells co‐expressed the CD33 antigen, and macrophage (Mac) colony‐forming cells predominated among total colony‐forming cells of CD34+ cells. In normal bone marrow cells, CD34+, CD33+ cells amounted to about 40% of CD34+ cells, and the incidences of erythroid bursts, granulocyte/macrophage (GM) colonies, and Mac colonies were similar to each other. After more than 10 weeks, CD34+, CD33− cells gradually recovered, as erythroid burst colony‐forming cells increased following GM colony‐forming cells. This phenomenon was well‐correlated with the time course of peripheral blood cell recovery. CD34+, CD33+ cells as committed progenitors and CD34+, CD33− cells as multipotent stem cells have distinctive biological behaviors in BMT.
KW - Bone marrow transplantation
KW - CD34 cells
KW - Hematopoietic stem cells
UR - http://www.scopus.com/inward/record.url?scp=0025857667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025857667&partnerID=8YFLogxK
U2 - 10.1111/j.1349-7006.1991.tb01885.x
DO - 10.1111/j.1349-7006.1991.tb01885.x
M3 - Article
C2 - 1712005
AN - SCOPUS:0025857667
SN - 0910-5050
VL - 82
SP - 547
EP - 552
JO - Japanese Journal of Cancer Research
JF - Japanese Journal of Cancer Research
IS - 5
ER -